VivoSeq
Other

Cognitive Decline

0

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Cognitive Decline is an early-stage landscape with 0 programs across 4 companies. The most active players are Avid Radiopharmaceuticals, Pfizer, Syndesi Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avid Radiopharmaceuticals

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalS

Syndesi Therapeutics

0 programs

PreclinicalU

Università degli Studi di Trento

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

29

clinical trials

Completed19 · 66%
Recruiting3 · 10%
Unknown status3 · 10%
Terminated2 · 7%
Active, not recruiting2 · 7%

Clinical Trials

Trial Activity

29 trials

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
Recruiting·MMichal Schnaider Beeri, Ph.D.·Phase 2·NCT07392723·20 enrolled
Cognitive Decline and Underlying Mechanisms in Asymptomatic Intracranial Artery Stenosis Patients
Recruiting·—·N/A·NCT05504330·100 enrolled
Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
Recruiting·—·N/A·NCT06336174·100 enrolled
Preventing Cognitive Decline with Metformin
Active, not recruiting·GGarvan Institute of Medical Research·Phase 3·NCT04511416·242 enrolled
Multimodal METformin and FINGER Lifestyle Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia: a Phase IIb Multi-national Randomised, Controlled Trial
Active, not recruiting·IImperial College London·Phase 2·NCT05109169·600 enrolled
Cognitive Decline in Non-demented PD
Completed·OOregon Health and Science University·Phase 4·NCT01340885·9 enrolled
Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
Completed·AAvid Radiopharmaceuticals·Phase 3·NCT01400425·239 enrolled
Statins, Cholesterol and Cognitive Decline in Alzheimer's
Completed·KKarolinska Institutet·N/A·NCT06635252·2,000 enrolled
Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training
Completed·WWashington University School of Medicine·Phase 4·NCT03272711·129 enrolled
Donepezil in the Prevention of Post-Operative Cognitive Decline
Completed·Pfizer logoPfizer·Phase 4·NCT00182845·30 enrolled
Arterial Spin Labeling (ASL) MRI for Cognitive Decline
Completed·UUniversity of Pennsylvania·N/A·NCT01727622·102 enrolled
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
Completed·UUniversity Hospital, Tours·Phase 1·NCT02062099·25 enrolled
Treatment With Namenda in Women at Risk for Cognitive Decline
Completed·SStanford University·N/A·NCT00242632·22 enrolled
A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline
Completed·—·N/A·NCT01669915·3,424 enrolled
Modafinil to Prevent Postoperative Cognitive Decline
Completed·TThe Cooper Health System·Phase 2·NCT03914118·137 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)